Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 3,201–3,208 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Pfizer Inc. TUKYSA, trastuzumab, and pertuzumab - (HER2CLIMB-05) HER2+ Metastatic Breast Cancer PDUFA Data Released Oral Intravenous Intravenous Oncology
Pfizer Inc. KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) Muscle-invasive bladder cancer (MIBC) PDUFA Data Released Intravenous Oncology
Pfizer Inc. KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) Muscle-invasive bladder cancer (MIBC) PDUFA Data Released Intravenous Oncology
Pfizer Inc. TUKYSA, trastuzumab, and pertuzumab - (HER2CLIMB-05) HER2+ Metastatic Breast Cancer PDUFA Data Released Oral Intravenous Intravenous Oncology
Pfizer Inc. Vepdegestrant (ARV-471) - (VERITAC-2) Breast cancer PDUFA Ongoing Oral Oncology
Pfizer Inc. Samuraciclib (CT7001) and vepdegestrant (ARV-471) ER+, HER2- metastatic breast cancer PDUFA Ongoing Oral Oncology
Pfizer Inc. MYFEMBREE (relugolix, estradiol and norethindrone acetate) Heavy menstrual bleeding associated with uterine fibroids BLA Filing Oral Women's Health
Pfizer Inc. Relugolix (combination) - (SPIRIT) Endometriosis sNDA Filing Oral Women's Health